1
|
Harvey RD, Miller TM, Hurley PA, Thota R, Black LJ, Bruinooge SS, Boehmer LM, Fleury ME, Kamboj J, Rizvi MA, Symington BE, Tap WD, Waterhouse DM, Levit LA, Merrill JK, Prindiville SA, Pollastro T, Brewer JR, Byatt LP, Hamroun L, Kim ES, Holland N, Nowakowski GS. A call to action to advance patient-focused and decentralized clinical trials. Cancer 2024; 130:1193-1203. [PMID: 38193828 DOI: 10.1002/cncr.35145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2024]
Abstract
This commentary is a call to action for a concerted commitment and effort to transform clinical trials and enable people with cancer to participate in clinical trials closer to home. Three key strategies are identified to address major barriers: confront challenges with the interpretation of US Food and Drug Administration Form 1572 requirements (Statement of Investigator); broaden acceptance of local laboratories and imaging centers; and invest in the creation of effective, sustainable partnerships between research centers and local providers.
Collapse
Affiliation(s)
- R Donald Harvey
- Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
| | - Therica M Miller
- Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York, USA
| | | | - Ramya Thota
- Intermountain Health, Salt Lake City, Utah, USA
| | | | | | - Leigh M Boehmer
- Association of Community Cancer Centers, Rockville, Maryland, USA
| | - Mark E Fleury
- American Cancer Society Cancer Action Network, Washington, District of Columbia, USA
| | | | | | | | - William D Tap
- Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | | | - Laura A Levit
- American Society of Clinical Oncology, Alexandria, Virginia, USA
| | | | - Sheila A Prindiville
- National Cancer Institute Coordinating Center for Clinical Trials, Bethesda, Maryland, USA
| | - Teri Pollastro
- Metastatic Breast Cancer Alliance, Mercer Island, Washington, USA
| | - Jamie R Brewer
- US Food and Drug Administration, Rockville, Maryland, USA
| | - Leslie P Byatt
- New Mexico Cancer Care Alliance, Albuquerque, New Mexico, USA
| | | | | | - Nicole Holland
- American Society of Clinical Oncology, Alexandria, Virginia, USA
| | | |
Collapse
|
2
|
Fernández-Ortega P, Diez de los Ríos de la Serna C. Componentes del edadismo o ageismo en la atención al paciente oncológico: una reflexion necesaria. Enfermería Clínica 2023. [DOI: 10.1016/j.enfcli.2022.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
3
|
Fernández-Ortega P, Ríos de la Serna CDDL. Components of ageism in oncologic patient care: A necessary reflection. Enferm Clin (Engl Ed) 2023; 33:1-3. [PMID: 36707217 DOI: 10.1016/j.enfcle.2022.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Accepted: 12/19/2022] [Indexed: 01/26/2023]
Affiliation(s)
- Paz Fernández-Ortega
- Coordinadora cap de Investigación en cuidados, Institut Català de Oncologia, Facultad de Medicina y Ciencias de la Salud. Profesora asociada, Departamento de Salud Pública, Mental y maternoinfantil. Bellvitge Campus, Universidad de Barcelona.
| | - Celia Diez de Los Ríos de la Serna
- Coordinadora cap de Investigación en cuidados, Institut Català de Oncologia, Facultad de Medicina y Ciencias de la Salud. Profesora asociada, Departamento de Salud Pública, Mental y maternoinfantil. Bellvitge Campus, Universidad de Barcelona
| |
Collapse
|
4
|
Gaddy JJ, Gross CP. Addressing Racial, Ethnic, and Age Disparities in Cancer Clinical Trial Enrollment: Time to Stop Tinkering Around the Edges. JAMA Oncol 2022; 8:1792-1793. [PMID: 36301581 DOI: 10.1001/jamaoncol.2022.5006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Jacquelyne J Gaddy
- Medical Oncology, Yale School of Medicine, New Haven, Connecticut.,Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center, New Haven, Connecticut
| | - Cary P Gross
- Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center, New Haven, Connecticut.,Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut
| |
Collapse
|
5
|
Marron JM, Hantel A, Abel GA, Peppercorn JM. Ethics Consultation in Oncology: The Search for Quality in Quantity. JCO Oncol Pract 2022; 18:610-613. [PMID: 35947815 PMCID: PMC9509056 DOI: 10.1200/op.22.00440] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Accepted: 07/11/2022] [Indexed: 09/03/2023] Open
Affiliation(s)
- Jonathan M. Marron
- Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
- Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA
- Center for Bioethics, Harvard Medical School, Boston, MA
- Office of Ethics, Boston Children's Hospital, Boston, MA
| | - Andrew Hantel
- Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA
- Center for Bioethics, Harvard Medical School, Boston, MA
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
| | - Gregory A. Abel
- Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA
- Center for Bioethics, Harvard Medical School, Boston, MA
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
| | - Jeffrey M. Peppercorn
- Center for Bioethics, Harvard Medical School, Boston, MA
- Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA
| |
Collapse
|
6
|
Stevenson J, DeGroote NP, Keller F, Brock KE, Bergsagel DJ, Miller TP, Cornwell P, Fasano R, Chonat S, Castellino SM. Characteristics and outcomes of pediatric oncology patients at risk for guardians declining transfusion of blood components. Cancer Rep (Hoboken) 2022; 6:e1665. [PMID: 35792092 PMCID: PMC9875642 DOI: 10.1002/cnr2.1665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 06/01/2022] [Accepted: 06/17/2022] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Transfusion of blood products is a necessary part of successful delivery of myelosuppressive regimens in pediatric cancer. There is a paucity of literature characterizing outcomes or management of pediatric patients with cancer when transfusion is declined. AIMS The objective of this paper is to describe the clinical characteristics, care, and outcomes of patients with cancer at risk for declining transfusion. METHODS AND RESULTS A retrospective cohort of patients aged 0-21 years with cancer managed at Children's Healthcare of Atlanta between 2006 and 2020 and with ICD-9 codes indicating risk of "transfusion refusal" or Jehovah's witness (JW) religion was identified. Demographics, disease, and management were abstracted. Descriptive statistics were performed to examine associations with transfusion receipt. Among 35 eligible patients identified as at risk for declining transfusion, 89% had primary guardians who identified as JW, and 45.7% identified as Black, non-Hispanic. Only 40% of guardians actively declined transfusion. Transfusion recipients had significantly lower hemoglobin (g/dl) and platelet counts (1000/μl) at initial presentation (9.6 vs. 11.9, p < .002 and 116.0 vs. 406.5, p = .001, respectively) and at nadir (5.9 vs. 8.7, p < .001 and ≤ 10 vs. 154, p < .001, respectively) than non-recipients. Legal intervention was required in 36.4% of those who ultimately received a transfusion. CONCLUSION Among pediatric cancer patients whose medical record initially indicated a preference for no transfusion, 60% of guardians accepted blood products when prescribed for oncology care. Guidelines for systematic management and transfusion sparing approaches are needed to honor guardian's preferences when possible yet while maintaining equitable cancer outcomes in this population.
Collapse
Affiliation(s)
- Jason Stevenson
- Department of Pediatrics, Division of Graduate Medical EducationEmory UniversityAtlantaGeorgiaUSA
| | - Nicholas P. DeGroote
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of AtlantaAtlantaGeorgiaUSA
| | - Frank Keller
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of AtlantaAtlantaGeorgiaUSA,Department of Pediatrics, Division of Pediatric Hematology/OncologyEmory UniversityAtlantaGeorgiaUSA
| | - Katharine E. Brock
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of AtlantaAtlantaGeorgiaUSA,Department of Pediatrics, Division of Pediatric Hematology/OncologyEmory UniversityAtlantaGeorgiaUSA,Department of Pediatrics, Division of Pediatric Palliative CareEmory UniversityAtlantaGeorgiaUSA
| | - D. John Bergsagel
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of AtlantaAtlantaGeorgiaUSA,Department of Pediatrics, Division of Pediatric Hematology/OncologyEmory UniversityAtlantaGeorgiaUSA
| | - Tamara P. Miller
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of AtlantaAtlantaGeorgiaUSA,Department of Pediatrics, Division of Pediatric Hematology/OncologyEmory UniversityAtlantaGeorgiaUSA
| | - Patricia Cornwell
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of AtlantaAtlantaGeorgiaUSA
| | - Ross Fasano
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of AtlantaAtlantaGeorgiaUSA,Department of Pediatrics, Division of Pediatric Hematology/OncologyEmory UniversityAtlantaGeorgiaUSA
| | - Satheesh Chonat
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of AtlantaAtlantaGeorgiaUSA,Department of Pediatrics, Division of Pediatric Hematology/OncologyEmory UniversityAtlantaGeorgiaUSA
| | - Sharon M. Castellino
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of AtlantaAtlantaGeorgiaUSA,Department of Pediatrics, Division of Pediatric Hematology/OncologyEmory UniversityAtlantaGeorgiaUSA
| |
Collapse
|
7
|
Winn RA. Enrollment Matters: The Reality of Disparity and Pursuit of Equity in Clinical Trials. Cancer Discov 2022; 12:1419-1422. [PMID: 35652212 DOI: 10.1158/2159-8290.cd-22-0319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
SUMMARY Disparities in clinical trial enrollment persist, fortified by the foundation and historical ideologies undergirding clinical cancer research. The scientific community has an ethical responsibility to seize the current moment to deconstruct and reconstruct these paradigms for more equitable research.
Collapse
Affiliation(s)
- Robert A Winn
- Virginia Commonwealth University Massey Cancer Center, VCU Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
| |
Collapse
|
8
|
Ng JS, Hamilton DG. Assessing the impact of the COVID-19 pandemic on breast cancer screening and diagnosis rates: A rapid review and meta-analysis. J Med Screen 2022; 29:209-218. [PMID: 35593115 DOI: 10.1177/09691413221101807] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
OBJECTIVE The ongoing COVID-19 pandemic has caused an indefinite delay to cancer screening programs worldwide. This study aims to explore the impact on breast cancer screening outcomes such as mammography and diagnosis rates. METHODS We searched Ovid MEDLINE, Ovid Embase, medRxiv and bioRxiv between January 2020 to October 2021 to identify studies that reported on the rates of screening mammography and breast cancer diagnosis before and during the pandemic. The effects of 'lockdown' measures, age and ethnicity on outcomes were also examined. All studies were assessed for risk of bias using the Newcastle-Ottawa Scale (NOS). Rate ratios were calculated for all outcomes and pooled using standard inverse-variance random effects meta-analysis. RESULTS We identified 994 articles, of which 7 registry-based and 24 non-registry-based retrospective cohort studies, including data on 4,860,786 and 629,823 patients respectively across 18 different countries, were identified. Overall, breast cancer screening and diagnosis rates dropped by an estimated 41-53% and 18-29% respectively between 2019 and 2020. No differences in mammogram screening rates depending on patient age or ethnicity were observed. However, countries that implemented lockdown measures were associated with a significantly greater reduction in mammogram and diagnosis rates between 2019 and 2020 in comparison to those that did not. CONCLUSION The pandemic has caused a substantial reduction in the screening and diagnosis of breast cancer, with reductions more pronounced in countries under lockdown restrictions. It is early yet to know if delayed screening during the pandemic translates into higher breast cancer mortality.
Collapse
Affiliation(s)
- Jay Shen Ng
- Melbourne Medical School, Faculty of Medicine, Dentistry & Health Sciences, 569586The University of Melbourne, Melbourne, Australia.,Department of Medicine, Malacca General Hospital, Ministry of Health, Malaysia
| | - Daniel G Hamilton
- Melbourne Medical School, Faculty of Medicine, Dentistry & Health Sciences, 569586The University of Melbourne, Melbourne, Australia.,MetaMelb Research Group, School of BioSciences, 2281The University of Melbourne, Melbourne, Australia
| |
Collapse
|
9
|
Oyer RA, Hurley P, Boehmer L, Bruinooge SS, Levit K, Barrett N, Benson A, Bernick LA, Byatt L, Charlot M, Crews J, DeLeon K, Fashoyin-Aje L, Garrett-Mayer E, Gralow JR, Green S, Guerra CE, Hamroun L, Hardy CM, Hempstead B, Jeames S, Mann M, Matin K, McCaskill-Stevens W, Merrill J, Nowakowski GS, Patel MI, Pressman A, Ramirez AG, Segura J, Segarra-Vasquez B, Hanley Williams J, Williams JE, Winkfield KM, Yang ES, Zwicker V, Pierce LJ. Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. J Clin Oncol 2022; 40:2163-2171. [PMID: 35588469 DOI: 10.1200/jco.22.00754] [Citation(s) in RCA: 58] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication.
Collapse
Affiliation(s)
- Randall A Oyer
- Penn Medicine Lancaster General Health Ann B Barshinger Cancer Institute, Lancaster, PA
| | | | - Leigh Boehmer
- Association of Community Cancer Centers, Rockville, MD
| | | | - Kathryn Levit
- American Society of Clinical Oncology, Alexandria, VA
| | - Nadine Barrett
- Duke Clinical and Translational Science Institute, Raleigh, NC
| | - Al Benson
- Northwestern University, Evanston, IL
| | | | - Leslie Byatt
- University of New Mexico Comprehensive Cancer Center, Albuquerque, NM
| | | | | | - Kyle DeLeon
- American Cancer Society Cancer Action Network, Washington, DC
| | - Lola Fashoyin-Aje
- US Food and Drug Administration Oncology Center of Excellence, Silver Spring, MD
| | | | | | - Sybil Green
- American Society of Clinical Oncology, Alexandria, VA
| | - Carmen E Guerra
- University of Pennsylvania Raymond and Ruth Perelman School of Medicine, Philadelphia, PA
| | - Leila Hamroun
- ChristianaCare Oncology Patient Advocates for Clinical Trials, Newark, DE
| | - Claudia M Hardy
- University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Eddy S Yang
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL
| | | | | |
Collapse
|
10
|
Booker R, Haase KR. Virtual Cancer Care Equity in Canada: Lessons From COVID-19. Clin J Oncol Nurs 2022; 26:224-227. [PMID: 35302552 DOI: 10.1188/22.cjon.224-227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The COVID-19 pandemic radically shifted healthcare delivery to patients with cancer. Virtual cancer care, or the remote delivery of health care, has become an important resource for patients in Canada to maintain access to cancer care during the pandemic. With an increased number of people regularly accessing the internet and smartphones being ubiquitous for nearly all ages, technology in health care has grown. Virtual cancer care has been referenced as the fourth pillar of cancer care and it appears it may be here to stay. This article explores the benefits and challenges associated with virtual cancer care and outlines the importance of ensuring it is safe and equitable. Oncology nurses can identify where virtual care can be used to mitigate inequities and call attention when these tools exacerbate inequities.
Collapse
|
11
|
Koo K, Papa N, Evans M, Jefford M, IJzerman M, White V, Evans SM, Ristevski E, Emery J, Millar J. Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography. BMC Cancer 2022; 22:283. [PMID: 35296282 PMCID: PMC8928643 DOI: 10.1186/s12885-022-09389-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2021] [Accepted: 03/04/2022] [Indexed: 11/30/2022] Open
Abstract
Background Prostate cancer is the most common internal malignancy in Australian men, and although most patients have good survival outcomes, treatment toxicities can impair function, leading to diminished quality of life for prostate cancer survivors. Socioeconomic disadvantage and geographical remoteness have been shown to be related to worse oncologic outcomes, and it is expected that they would similarly influence functional outcomes in prostate cancer. Methods Using data from the Victorian Prostate Cancer Outcomes Registry (n = 10,924), we investigated functional outcomes as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC-26) following prostate cancer treatment, focusing on associations with socioeconomic status and geographical remoteness and controlling for clinicopathologic characteristics. A single composite score was developed from the five separate EPIC-26 domains for use in geo-mapping. Results A total of 7690 patients had complete EPIC-26 data, allowing mapping hotspots of poor function using our composite score. These hotspots were observed to relate to areas of socioeconomic disadvantage. Significant heterogeneity in outcomes was seen in urban areas, with hotspots of good and poor function. Both socioeconomic disadvantage and geographical remoteness were found to predict for worse functional outcomes, although only the former is significant on multivariate analysis. Conclusions Geo-mapping of functional outcomes in prostate cancer has the potential to guide health care service provision and planning. A nuanced policy approach is required so as not to miss disadvantaged patients who live in urban areas. We have demonstrated the potential of geo-mapping to visualise population-level outcomes, potentially allowing targeted interventions to address inequities in quality of care. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-022-09389-4.
Collapse
Affiliation(s)
- Kendrick Koo
- Radiation Oncology, Alfred Health, Melbourne, Australia. .,School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. .,Department of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria, Melbourne, Australia. .,Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
| | - Nathan Papa
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| | - Melanie Evans
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| | - Michael Jefford
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.,Department of Health Services Research, Peter MacCallum Cancer Centre, Victoria, Melbourne, Australia
| | - Maarten IJzerman
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.,Centre for Cancer Research, Cancer Health Services Research, University of Melbourne, Victoria, Australia
| | - Victoria White
- School of Psychology, Deakin University, Victoria, Australia.,Cancer Council Victoria, Melbourne, Australia
| | - Sue M Evans
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.,Cancer Council Victoria, Melbourne, Australia
| | - Eli Ristevski
- Monash Rural Health - Warragul, Monash University, Victoria, Australia
| | - Jon Emery
- Centre for Cancer Research, Cancer Health Services Research, University of Melbourne, Victoria, Australia
| | - Jeremy Millar
- Radiation Oncology, Alfred Health, Melbourne, Australia.,School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| |
Collapse
|